We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia

News   Dec 11, 2009

 
Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia
 
 
 

RELATED ARTICLES

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

Perfecting a Method To Predict the Potential of New Drugs

News

Researchers are perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

READ MORE

Chemical Reaction Method Makes Drug Production More Efficient

News

Researchers have created a more efficient method to produce the building blocks needed for cancer treatment drugs and antibiotics.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE